MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties

Fulcrum Therapeutics, Inc.

MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.
Fulcrum forfeits all future milestone payments (up to $298.5M per target), royalties, and research cost reimbursement.
Fulcrum had received $10M upfront, $2.5M prepaid research funding, and achieved a $2.5M preclinical milestone.
Parties will continue obligations until June 26, 2025; no further revenues from the agreement after termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.